focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Awful company and feel genuinely sorry for long term holders. Warning signs were there - the COO and some of the scientists failed massively at GE Healthcare, delivered nothing and took big redundancy packages. We had a trip to Cardiff escape rooms where the COO and Senior Scientist led a team that had to be rescued by management after 2 hours. Aim was always to demonstrate the right corporate behaviours to cover up for idiocy. Some also happy to take a salary from Celixr. Terrible people with no morals. Managed to waste years at GE developing awful products that were never going to launch, but had no spine to say anything. Got rid of any outsiders whilst protecting lab technicians on high salaries. Then repeat the trick elsewhere. Low life scumbags.
Twenty plus years I have held this share I stupidly thought my kids would prosper how wrong was I, never no sign of a divy, to many chiefs and no indians they need to pull a white rabbit out of the hat, not fresh air.
You should check your maths old man, Iain's holdings would have cost him less than £50k
They still have time, but the SP tells you that the clock is ticking. Everyone knows that, including Iain and the rest of the team. I agree, some more inside buying will probably be required for any of us to follow suit. I bought in here as a bit of a punt after Iain joined, and am willing to see what happens, with my eyes fully open. Expectations suitable for the risk profile too. Would probably take a few more if he did another 100K (or more) buy. Buttons at this price! Good weekend all.
Just added up the cost of Iain Ross’s holdings and he’s spent almost £90k on them. However, considering how much the SP has fallen recently, if he’s not tempted to buy a lot more at these prices, then I don’t hold out much hope for the company. Just one deal would transform sentiment and the latest results still suggests that deals will follow over the next year. I do hope so - I’ve lost a shedload!
Rene has no news it needs to change it,s name to bag of crap it will not last another year.
Didn't catch the update today.... obviously nothing of note hence the drop....I'm 97% down so may as well hang on for a miracle.....
Iain's purchases amount to less than £50k, which is nominal in the scheme of things
I guess, given Thursday is happening Rene is still deemed a going concern. If correct that seems to indicate the erstwhile Mr Ross is not going to liquidate or cease trading, certainly anytime soon, which may even suggest us budding alchemists, astrologers, and delusionists will be in work for a while longer too - yeah.
Fair enough. Absolutely not one for widows or orphans! And I also agree pretty much last chance saloon here. Have to disagree on what a nominal holding is though, because IMO what Iain purchased here is not really beer money. A few other employees also took a few too, albeit on a smaller scale than Iain of course.
Death or glory? Not long to find out! GLA
I've been in with ETX since 2.75p and C4XD since the lofty heights of 40p, although average is now 24p. I agree that the jury is still out with them but the difference is they have no issue raising funds - when they do, it's at nearly zero discount to the SP. Ali Mortazavi and Clive Dix are longstanding and very well respected figureheads who have a lot of skin in the game (Iain Ross has only a nominal holding in RENE). I still believe both companies will be bought out by big pharma in due course.
RENE are very much in the last chance saloon, and it's a binary play with a very short runway. I just think if it was a commercially attractive product, they would have secured agreements by now but this week will reveal more. Good luck to all remaining holders, but I no longer have the faith here
Well, very similar if you were a holder from the beginning in all of them, from the various charts! Not saying C4 or ETX (which I did not mention, but do vaguely remember glancing at a few years ago, now you have cited it) are going the same way as 4D, but the jury will presumably be out on those until they are profitable. Do like the look of the free float on ETX though, now I have had a look. Market caps and shares in issue in both are not comparable to RENE though, who under Iain is now (I think) well managed and he is personally invested too. I assume he thinks they have commercially attractive products to have taken the job, let alone purchased a respectable amount of shares from his own pocket as well. But the clock is ticking and all holders here will know that the window of opportunity to prove commercial viability is small. Hence the m/cap today.
All of this kind of proves my point though - the time, capital investment and opportunity cost in this space does not look pretty. Unless you bought and sold the bubbles, which I did in a couple, but made the mistake of investing, rather than trading these types. Will this have longer term ramifications for investment in this space in future, was more the point I have been pondering. Perhaps the big boys will have to go back to doing all their own R&D, rather than snapping up the odd small cap drug discovery outfit that finds success?
I don't think you can put C4XD or ETX in the same boat as RENE and 4D!!!
I take on board your point about the performance of some boards (I have been in a shareholder in all the aforementioned) but those are the risks you take when you invest. 4D got carried away with easy finance environment which then ran out. I'm not convinced RENE actually have a commercially attractive product unfortunately. I have far greater hope for ETX and C4XD, both of which are well managed companies, with directors who are personally invested
Spot on, Porky, although I have been impressed with Iain so far. Took a small punt off the back of his joining. Whether he can turn this one around, remains to be seen. Unlike so many AIM BODs though, he actually has a track record of success - and has put some of his own money in too. Still a high risk venture and I am under no illusions as to binary nature of this one.
Longer term, it will be interesting to see what, if any, impact the historically inept and greedy BOD activity, spanning so many of these types of outfits, will have on the approach to investing in the small cap bio field.
For me, I would not touch this area again in the small cap world. I hold here and a larger amount over at Evgen pharma, but IMO the risk/reward is simply unattractive now, so am not looking at any others. In the past, I had considered a few others like VAL and C4DX. I take a cursory glance over there now and again, but not remotely tempted! It does not help with the lack of consequences for failure and/or fraud that is so common on AIM it seems. Take 4D, which we both had the misfortune of being in. None of those directors should ever be allowed to hold a similar company position again IMO. They should also be investigated, to ensure it was 'only' their personal commercial uselessness that led to that outcome over there. Long jail terms and financial ruin, if otherwise. But we all know how very rare such things are, so AIM will remain a cesspit. Anyway, in danger of turning this into a rant now :) The sun is shining and life is too short! GLA.
As at 30 November 2022, having recently received the R&D tax credit for FY 2022, the Company has cash of £10.0 million, and through deferring certain expenditure on proprietary programmes and other longer term development plans, the cash runway will be extended until at least the start of the fourth calendar quarter of 2023. This is not expected to compromise the Company's ability to sign commercial exosome collaborations which upon completion should extend the runway until at least 2024.
Notice there selling down, at one time they had a director on board, helped them with finance,
What is real sad is that just like a lot of these plays, its only when they are right up against it they start taking cash burn more seriously and look at costs. The previous results albeit horrendous cash burn did show improvements.
The previous funding boom for biotech's on balance hasn't helped investors one jot IMO, money has come far too easy to some of these businesses and they just haven't valued it, just spent money without regard because well they can. Then they end up in dire trouble because they are stuck with previous spending commitments and now we are in a prolonged funding drought there are few places to turn.
Interested to see what the results come out like. I suspect there will be improvements but with the commitments and high pay roll how can you address that? the BOD will be feeling the heat now for sure. Hope they can pull something out the hat for sure.
Presentation on Investor meet company on the 25th, good luck.
Actions need urgently there needs to be a breakthrough pronto or this share will go down the sewer to much red tape a positive anousment to the media would HELP, ADVERTISE There must be some glimmer of hope.
Cash will be dwindling by the day, much like the SP
Valued at 3.86m now. Way under cash! Crazy
No matter what happens and which ever way you cut it I’ve lost my shirt on Rene. So an historical lens is now a nonsensical and an unproductive way to look at this share. The fact I’ve had it for over a decade is meaningless. As Dibs suggests however does the present eight cents provide an opportunity whilst there’s still life to make 40 or even 100% on the price? It may well do (or maybe it won’t) but good luck to those taking that chance. At least it won’t take years for you to know the outcome of your bet.
Cash getting eaten into not much value will be put on that.
The two 20k trades just printed look like sells but they are both buys by me.
Happy to be buying at a valuation of £4.7m which is substantially less than cash in bank!
Had great promise nice write up in the papers then and here we are still . IMO pharma are back as its been crushed so much .
Like the 100 to one shot at Belmont, still on the track and maybe even worth something as horse meat but sadly it doesn’t mean it’ll win. But my dollar landed on its nose over a decade ago so will watch the race until the end, even if I wont hold my breath. But good luck to all still betting.